(5-甲基-2-苯基-1,3-噁唑-4-基)甲胺 | 132451-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (5-甲基-2-苯基-1,3-噁唑-4-基)甲胺
• 中文别名: (5-甲基-2-苯基-4-恶唑基)甲胺；(5-甲基-2-苯基-1,3-恶唑-4-基)甲胺；(5-甲基-2-苯基-恶唑-4-基)甲胺
• 英文名称: 1-(5-methyl-2-phenyl-1,3-oxazol-4-yl)methanamine
• 英文别名: N-[(5-Methyl-2-phenyl-4-oxazolyl)methyl]amine；C-(5-methyl-2-phenyloxazol-4-yl)methylamine；(5-methyl-2-phenyl-4-oxazolyl)methylamine；5-methyl-2-phenyloxazol-4-ylmethylamine；(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methylamine；(5-methyl-2-phenyl-1,3-oxazol-4-yl)methanamine
• CAS: 132451-28-6
• 化学式: C₁₁H₁₂N₂O
• mdl: MFCD08271882
• 分子量: 188.229
• InChiKey: LEKZZMAVLLJSNA-UHFFFAOYSA-N

物化性质

• 熔点：
  42 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  (5-甲基-2-苯基-1,3-噁唑-4-基)甲胺 在 sodium tetrahydroborate 、 sodium triacetoxyborohydride 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 乙醇-D1 为溶剂， 生成 2-[4-[[Furan-2-ylmethyl-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid
  参考文献：
  名称：

  Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1)

  摘要：

  We describe here the design, syntheses and structure-activity relationships (SAR) of novel zwitterionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) alpha/gamma dual agonists. We commenced the medicinal research with compound 1 originated by Eli Lilly, which was reported to possess PPAR alpha/gamma dual agonist activity. We incorporated an amine linker and optimized it on the nitrogen of the linker, thereby envisioning the enhancement of the PPAR alpha/gamma dual agonist activity together with altering the physicochemical properties. As a result, we could generate compounds showing the PPAR alpha/gamma dual activity, especially among which compound 22e had a franylmethyl group on the linker and 2,6-dimethyl phenyl ring at the carboxylic acid head group furnishing a highly potent dual agonist activity, together with a great glucose lowering effect. Moreover, it remedied the lipid profile, that is, triglyceride without body weight gain in the db/db mice model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.092
• 作为产物：
  描述：

  (5-Methyl-2-phenyl-4-oxazolyl)methyl Azide 以82%的产率得到
  参考文献：
  名称：

  CLARK, DAVID A.;GOLDSTEIN, STEVEN W.;HULIN, BERNARD

  摘要：

  DOI：

文献信息

• Novel thiazolidine-2,4-diones as potent euglycemic agents.
  作者：Bernard Hulin、David A. Clark、Steven W. Goldstein、Ruth E. McDermott、Paul J. Dambek、Werner H. Kappeler、Charles H. Lamphere、Diana M. Lewis、James P. Rizzi

  DOI：10.1021/jm00088a022

  日期：1992.5

  A new series of thiazolidine-2,4-diones was obtained by replacing the ether function of englitazone with various functional groups, i.e., a ketone, alcohol, or olefin moiety. These compounds lower blood glucose levels in the genetically obese and insulin-resistant ob/ob mouse. Appending an oxazole-based group at the terminus of the chain provided highly potent compounds.

  通过用各种官能团即酮，醇或烯烃部分取代恩格列酮的醚官能团，获得了一系列新的噻唑烷-2,4-二酮。这些化合物可降低遗传性肥胖和胰岛素抵抗的ob / ob小鼠的血糖水平。在链的末端附加基于恶唑基的基团提供了高效的化合物。
• NEW COMPOUNDS I/418
  申请人：Bjore Annika

  公开号：US20080015237A1

  公开（公告）日：2008-01-17

  There is provided compounds of formula I, wherein R 1 to R 7 have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

  提供了式I的化合物， 其中R1至R7在描述中给出了它们的含义，这些化合物在预防和治疗心律失常方面非常有用，特别是房性和室性心律失常。
• Thiazolidinedione derivatives as hypoglycemic agents
  申请人：Pfizer Inc.

  公开号：US05330998A1

  公开（公告）日：1994-07-19

  Hypoglycemic thiazolidine-2,4-dione derivatives of the formula ##STR1## wherein the dotted line represents a bond or no bond; V is --CH.dbd.CH--, --N.dbd.CH--, --CH.dbd.N--, S, O or NR; W is S, SO, SO.sub.2, SO.sub.2 NR.sup.1, NR.sup.1 SO.sub.2, CONR.sup.1 or NR.sup.1 CO; X is S, O, NR.sup.2, --CH.dbd.N-- or --N.dbd.CH; Y is CH or N; Z is hydrogen, (C.sub.1 -C.sub.7)alkyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, pyridyl, furyl, thienyl or phenyl mono- or disubstituted with the same or different groups which are (C.sub.1 -C.sub.3)alkyl, trifluoromethyl, (C.sub.1 -C.sub.3)alkoxy, fluoro, chloro or bromo; Z.sup.1 is hydrogen or (C.sub.1 -C.sub.3)alkyl; R, R.sup.1 and R.sup.2 are each independently hydrogen or (C.sub.1 -C.sub.4); and n is 1, 2 or 3; a pharmaceutically acceptable cationic salt thereof; or a pharmaceutically acceptable acid addition salt thereof when the compound contains a basic nitrogen.

  具有以下结构的降糖噻唑烷-2,4-二酮衍生物的中文翻译：其中虚线代表键或无键；V为--CH.dbd.CH--, --N.dbd.CH--, --CH.dbd.N--, S, O或NR；W为S, SO, SO.sub.2, SO.sub.2 NR.sup.1, NR.sup.1 SO.sub.2, CONR.sup.1或NR.sup.1 CO；X为S, O, NR.sup.2, --CH.dbd.N--或--N.dbd.CH；Y为CH或N；Z为氢，(C.sub.1 -C.sub.7)烷基，(C.sub.3 -C.sub.7)环烷基，苯基，吡啶基，呋喃基，噻吩基或苯基，单取代或双取代，取代基为相同或不同的基团，包括(C.sub.1 -C.sub.3)烷基，三氟甲基，(C.sub.1 -C.sub.3)烷氧基，氟，氯或溴；Z.sup.1为氢或(C.sub.1 -C.sub.3)烷基；R，R.sup.1和R.sup.2各自独立地为氢或(C.sub.1 -C.sub.4)；n为1，2或3；其药学上可接受的阳离子盐；或者当化合物含有碱性氮时，其药学上可接受的酸加盐。
• 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07179823B1

  公开（公告）日：2007-02-20

  A compound of formula (I) F wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; x represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: —CO—, —CS—, —CR4(OR5)— or —NR6— wherein each of R4 and R6 represents a hydrogen atom or a hydrocarbon group which may be stubstituted, R5 represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: —SO—, —SO2—, —NR7—, —CONR7— or —NR7CO— wherein R7 represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group.

  化合物的式子为（I）F，其中R1代表一个可以被取代的碳氢基团或杂环基团；x代表一个键、一个氧原子、一个硫原子或者一个式子为：—CO—、—CS—、—CR4(OR5)—或—NR6—的基团，其中R4和R6分别代表一个氢原子或者一个可以被取代的碳氢基团，R5代表一个氢原子或者一个羟基的保护基团；m代表一个0到3的整数；Y代表一个氧原子、一个硫原子或者一个式子为：—SO—、—SO2—、—NR7—、—CONR7—或—NR7CO—的基团，其中R7代表一个氢原子或者一个可以被取代的碳氢基团；环A代表一个芳香环，可以有1到3个取代基；n代表一个1到8的整数；环B代表一个含氮的5元杂环，可以有一个烷基的取代基。
• Phenoxyacetic Acid Derivatives and Drug Comprising The Same
  申请人：Kagechika Katsuji

  公开号：US20070208021A1

  公开（公告）日：2007-09-06

  Novel compounds having excellent PPAR α/γ agonist effects and having desirable properties for medicaments are provided. Peroxisome proliferator-activated receptor α/γ agonists of the general formula (I): (wherein Q is an optionally-substituted benzene or pyridine ring; R 1 and R 2 each are an optionally-substituted phenyl group or 5- or 6-membered aromatic heterocyclic group; X Y, and Z are independently C, O, S or N; R 3 to R 9 each are a hydrogen atom, a lower alkyl group, etc.; n is an integer of 0 to 3).

  提供了具有出色的PPAR α/γ激动剂效果和适合于药物的理想特性的新型化合物。一般式(I)的过氧化物增殖物激活受体α/γ激动剂如下：（其中Q是可选取代苯环或吡啶环；R1和R2分别是可选取代苯基或5-或6-成员芳香杂环基；X、Y和Z独立地是C、O、S或N；R3到R9每个是氢原子、低级烷基等；n是0到3的整数）。